Regeneron Pharmaceuticals Inc (REGN)

Debt-to-assets ratio

		Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Long-term debt	US$ in thousands	1,982,900	1,981,400	1,980,000	1,978,500	0
Total assets	US$ in thousands	33,080,200	29,214,500	25,434,800	17,163,300	14,805,200
Debt-to-assets ratio		0.06	0.07	0.08	0.12	0.00

December 31, 2023 calculation

Debt-to-assets ratio = Long-term debt ÷ Total assets
= $1,982,900K ÷ $33,080,200K
= 0.06

The debt-to-assets ratio of Regeneron Pharmaceuticals, Inc. has fluctuated over the past five years, indicating changes in the company's debt management and asset utilization.

In 2019, the ratio was relatively low at 0.05, suggesting that the company had a lower proportion of debt compared to its total assets. Subsequently, in 2020, the ratio increased to 0.16, indicating a significant rise in debt relative to assets, which could imply increased financial leverage and risk.

However, in the following years, there was a downward trend in the ratio. By 2021, the ratio improved to 0.11, showing a more favorable balance between debt and assets. In 2022, the ratio further decreased to 0.09, indicating continued improvement in managing debt levels.

The most recent data for 2023 reflects a debt-to-assets ratio of 0.08, which suggests that the company has maintained a relatively low level of debt in relation to its assets. This trend indicates a conservative approach to financing operations and investments, potentially reducing financial risk and enhancing financial stability.

Overall, the declining trend in the debt-to-assets ratio from 2020 to 2023 indicates a more prudent debt management strategy by Regeneron Pharmaceuticals, Inc., potentially enhancing its financial health and stability.